Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + follitropin alfa
- Development stage
- Phase 4
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
"metformin + FSHr" is a combination treatment regimen consisting of the insulin-sensitizing small molecule metformin and recombinant follicle-stimulating hormone (FSHr). This regimen is primarily investigated for the treatment of infertility in women with clomiphene-resistant polycystic ovary syndrome (PCOS). Metformin acts by activating AMP-activated protein kinase (AMPK), which improves insulin sensitivity and reduces androgen production in the ovaries. Recombinant FSH (such as follitropin alfa) acts as an agonist at the follicle-stimulating hormone receptor (FSHR) on granulosa cells to stimulate follicular development and maturation. In the PERCING clinical trial (NCT00378729), this combination was used as part of an ovarian stimulation and intrauterine insemination (IUI) protocol to compare its efficacy against surgical laparoscopic ovarian drilling.
- Other names
- metformin + FSHrmetformin + recombinant follicle stimulating hormonemetformin + recombinant FSH
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)FSHR (Follicle-stimulating hormone receptor)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on metformin + follitropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + follitropin alfa.